MCRN Canadian-Designed Clinical Trial Inspires
a Global Phase III Trial

Dr Nizar Bahlis from the Tom Baker Cancer Institute in Calgary and Dr Christine Chen from the Princess Margaret Cancer Centre in Toronto were instrumental in the development of a global multi-centre myeloma phase II clinical trial, the STOMP (MCRN 002) trial, which is currently actively enrolling myeloma patients here in Canada.

For this particular trial, Canada is the leading investigator in this promising new molecule, selinexor or KPT-330, a first-in-class Selective Inhibitor of Nuclear Export (SINEā„¢) compound developed by Karyopharm Therapeutics in Boston. This has given eligible patients across Canada early access to an innovative therapy.

For details on this trial, visit the clinical trials section on our website HERE.
MCRN 005 - The BOSTON Trial 
Dr Nizar Bahlis
Inspired by the success of the Phase II MCRN 002 STOMP trial, Karyopharm has turned to MCRN investigators to participate and lead the Phase III global registration trial for selinexor. Only therapies that are effective, safe and have tolerable side effects can proceed to Phase III testing. Phase III trials compare the "standard of care" to the new treatment and are usually the largest, involving hundreds patients at cancer centres around the world. T he trial, which will be led by Dr. Nizar Bahlis of Calgary, will evaluate the combination of selinexor, bortezomib, and dexamethasone (SVd) compared to bortezomib and dexamethasone (Vd). 

Kudos to our Canadian team for promoting Canadian research to a global playing field and for bringing the MCRN to an international scale.  

What's happening in social media

  Facebook    Twitter    LinkedIn   View our videos on YouTube  View our photos on flickr   View on Instagram